BNTX BioNTech SE IFRS Annual reports only
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1776985 · Reporting currency EUR · Fiscal year ends 12/31
Financial factors as of 2025-12-31 (FY2025), by fiscal year; growth vs the previous fiscal year
Growth
Margins
Returns
Leverage & solvency
Cash quality & payout
Factor history charts and full statement history on Pro 🔒
Financial statements
| Unit: EUR | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | 2.87B | 2.75B |
| Cost of revenue | 641.80M | 541.30M |
| Gross profit | 2.23B | 2.21B |
| R&D expense | 2.10B | 2.25B |
| SG&A expense | 514.40M | 531.10M |
| Operating income | -1.40B | -1.31B |
| Interest expense | 14.20M | 16.90M |
| Pretax income | -1.05B | -677.70M |
| Income tax | 85.30M | -12.40M |
| Net income | -1.14B | -665.30M |
| EBITDA | -1.02B | -1.02B |
| EPS (basic) | -4.70 | -2.77 |
| EPS (diluted) | -4.70 | -2.77 |
| Weighted avg. shares (diluted) | 241.70M | 240.40M |
| Balance sheet | ||
| Cash & equivalents | 7.68B | 9.76B |
| Receivables | 924.20M | 1.46B |
| Inventory | 110.70M | 283.30M |
| Current assets | 16.15B | 18.80B |
| PP&E, netmay include right-of-use assets (IFRS) | 1.08B | 935.30M |
| Goodwill | 367.90M | 380.60M |
| Total assets | 21.99B | 22.53B |
| Current liabilities | 2.14B | 2.52B |
| Total liabilities | 2.76B | 3.12B |
| Shareholders' equity | 19.22B | 19.41B |
| Shares outstanding | 251.33M | 239.97M |
| Cash flow statement | ||
| Operating cash flow | 456.00M | 207.70M |
| Capital expenditure | 175.10M | 286.50M |
| Free cash flow | 280.90M | -78.80M |
| Investing cash flow | -2.47B | -2.08B |
| Financing cash flow | -52.90M | -45.90M |
| Depreciation & amortization | 382.80M | 298.00M |
| Stock-based compensation | 106.20M | 100.90M |
| Dividends paid | — | 0 |
Free plan shows the latest 2 periods; Pro shows all 9 🔒
· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.
· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.
· Amounts are in the company's reporting currency, EUR, not USD; the site does no currency conversion.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.